Navigation Links
d'Oliveira & Associates Issues New Infographic on Xarelto Providing Current FDA and Medical Study Information
Date:3/25/2013

(PRWEB) March 25, 2013

In July of 2011, the FDA announced that it had approved Xarelto to prevent deep vein thrombosis in patients undergoing hip or knee replacement surgery (i). In November, the FDA expanded Xarelto’s approval to include the prevention of stroke in patients with atrial fibrillation. One year later the FDA gave its approval of the drug to prevent the recurrence of blood clots. However, according to The New York Times, an FDA panel voted against approving Xarelto for the treatment of acute coronary syndrome (ACS) (ii). Specifically, the panel was concerned that 15 percent of the participants in a study of Xarelto and ACS dropped out.

According to QuarterWatch, a report published by the Institute for Safe Medication Practices, the FDA received 356 adverse event reports of “serious, disabling, or fatal injury” for Xarelto in the first quarter of 2012 (iii). Additionally, the report stated that blood clots “were the predominant serious adverse events reported, accounting for 158 cases.” By October, the FDA had received 2,754 adverse event reports concerning Xarelto. Among these were 386 cases of pulmonary embolism, 279 cases of deep vein thrombosis, and 107 cases of gastrointestinal hemorrhage (iv).

The Xarelto infographic provides a summary of drug information and lists possible side effects. Additionally, it provides information on a study published in the New England Journal of Medicine, which found that the anticoagulant drug may increase the risk of hemorrhaging (v). Visit the Xarelto section of d’Oliveira & Associates website and view the infographic here.

If you or a loved one has suffered Xarelto side effects, you may want to speak with a lawyer regarding a claim. A personal injury lawyer familiar with new developments in the investigation of Xarelto may be able to assist you in making important personal and legal decisions. Our firm is working with some of the most experienced Xarelto lawyers in the country who are handling these cases.

Please contact the law offices of d'Oliveira & Associates, P.C. at 1-800-992-6878 or fill out a contact form for a free legal consultation.

(i) drugs.com/history/xarelto.html
(ii) nytimes.com/2012/05/24/business/fda-panel-votes-against-expansion-of-xarelto.html?_r=4&src=recg&
(iii) ismp.org/quarterwatch/pdfs/2012Q1.pdf
(iv) http://www.adverseevents.com/drugdetail.php?AEDrugID=5158&BrandName=XARELTO
(v) nejm.org/doi/full/10.1056/NEJMoa1111096

Read the full story at http://www.prweb.com/releases/2013/3/prweb10551499.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. d'Oliveira & Associates Help New Bedford Woman Receive $95,000 in Damages for Dog Bite Injury Case #:NB-11736
2. d'Oliveira & Associates Helps Westport, MA Man Receive $100,000 Settlement for Reckless Driving Accident
3. d'Oliveira & Associates Helps Rhode Island Estate Receive the Maximum Compensation Under RI Law of $250,000 Settlement for Fatal Auto Accident
4. d'Oliveira & Associates Helps Newport Woman Receive $150,000 Settlement for Auto Accident; Case: MI-11889
5. The Law Firm of d'Oliveira & Associates Now Offers a No Win - No Fee Promise in Fosamax Cases
6. The Law Firm of d'Oliveira and Associates Now Offers a No Win - No Free Promise in Nexium Cases
7. d'Oliveira & Associates Notes the Announcement of Zoloft Birth Defects Multidistrict Litigation (MDL) Set to Start in Mid-September 2014
8. d'Oliveira & Associates Helps Fall River, MA Teenager Receive $38,500 in Auto Accident Settlement
9. D'Oliveira & Associates Now Offers a No Win No Fee Promise in Zithromax Cases
10. d'Oliveira & Associates Releases Fresenius Infographic about the FDA Recall of NaturaLyte and GranuFlo
11. The Law Firm of d'Oliveira & Associates Now Offers a No Win - No Fee Promise in Mirena IUD Cases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
(Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 , ... ... of their peers in Washington, D.C., for the 49th Congress of the International ... Ph.D ., Vice President of the Center for Cancer and Blood Disorders ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy ... health literacy software tool, and the Cancer Patient Education Network (CPEN), an independent ... today announce a new strategic alliance. , As CPEN’s strategic partner, HLI ...
Breaking Medicine News(10 mins):
(Date:10/7/2017)... 6, 2017   Provista, a proven leader ... billion in purchasing power, today announced a new resource ... The Newsroom is the online home for case ... expert bios, news releases, slideshows and events. ... wealth of resources at their fingertips, viewers can also ...
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
Breaking Medicine Technology: